Johnson & Johnson
Johnson & Johnson Shareholders Approve Key Proposals at 2026 Annual Meeting
Summary
At the 2026 Annual Meeting of Shareholders, Johnson & Johnson's shareholders elected all 12 director nominees to the Board of Directors, approved the executive compensation philosophy and compensation of named executive officers on an advisory basis, ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026, and did not approve the shareholder proposal to adopt a policy requiring an independent board chair.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement